NASDAQ : ERAS
Erasca, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 14.35 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.02B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 41.80M | 38.55M | 40.03M | 37.70M | 33.69M | 22.62M |
| Research & Development | 108.88M | 92.85M | 112.36M | 103.82M | 113.96M | 73.92M |
| Operating Expenses | 150.68M | 131.41M | 152.39M | 141.53M | 147.65M | 96.54M |
| Operating Income | -150.68M | -131.41M | -152.39M | -141.53M | -147.65M | -96.54M |
| Interest & Investment Income | 15.59M | 16.61M | 20.09M | 16.71M | 4.90M | 190.00K |
| Other Non Operating Income (Expenses) | -179.00K | -248.00K | 44.00K | -229.00K | -257.00K | -15.57M |
| EBT Excluding Unusual Items | -135.27M | -115.05M | -132.25M | -125.04M | -143.00M | -111.92M |
| Gain (Loss) on Sale of Investments | 47.00K | -2.20M | ||||
| Asset Writedown | -4.70M | |||||
| Other Unusual Items | 2.20M | |||||
| Pretax Income | -287.22M | -124.55M | -161.65M | -125.04M | -242.81M | -122.76M |
| Net Income | -287.22M | -124.55M | -161.65M | -125.04M | -242.81M | -122.76M |
| Net Income to Common | -287.22M | -124.55M | -161.65M | -125.04M | -242.81M | -122.76M |
| Shares Outstanding (Basic) | 295.80M | 283.53M | 233.82M | 150.18M | 122.02M | 66.29M |
| Shares Outstanding (Diluted) | 295.80M | 283.53M | 233.82M | 150.18M | 122.02M | 66.29M |
| EPS (Basic) | -0.97 | -0.44 | -0.69 | -0.83 | -1.99 | -1.85 |
| EPS (Diluted) | -0.97 | -0.44 | -0.69 | -0.83 | -1.99 | -1.85 |
| Free Cash Flow | -98.08M | -95.58M | -109.48M | -102.99M | -117.81M | -90.81M |
| Free Cash Flow Per Share | -0.33 | -0.34 | -0.47 | -0.69 | -0.97 | -1.37 |
| EBITDA | -147.74M | -128.30M | -148.58M | -137.79M | -145.01M | -95.71M |
| D&A For EBITDA | 2.94M | 3.11M | 3.81M | 3.73M | 2.64M | 829.00K |
| EBIT | -150.68M | -131.41M | -152.39M | -141.53M | -147.65M | -96.54M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 42.54M | 73.81M | 67.74M | 93.08M | 284.22M | 360.49M |
| Short-Term Investments | 226.20M | 202.27M | 230.57M | 219.28M | 151.40M | 53.99M |
| Cash & Short-Term Investments | 268.74M | 276.07M | 298.31M | 312.35M | 435.62M | 414.48M |
| Other Receivables | 2.50M | 2.50M | 2.30M | 1.10M | 748.00K | |
| Receivables | 2.50M | 2.50M | 2.30M | 1.10M | 748.00K | 100.00K |
| Prepaid Expenses | 7.20M | 7.66M | 8.18M | 7.23M | 8.13M | 5.44M |
| Total Current Assets | 278.44M | 286.24M | 308.79M | 320.68M | 444.50M | 420.02M |
| Property, Plant & Equipment | 39.39M | 42.33M | 48.54M | 60.19M | 65.23M | 33.31M |
| Long-Term Investments | 115.53M | 65.72M | 142.16M | 11.64M | 2.00M | 44.77M |
| Other Long-Term Assets | 1.69M | 1.86M | 3.03M | 2.79M | 3.18M | 3.32M |
| Total Assets | 435.05M | 396.15M | 502.53M | 395.30M | 514.91M | 501.42M |
| Accounts Payable | 2.02M | 981.00K | 468.00K | 2.00M | 23.05M | 4.68M |
| Accrued Expenses | 26.11M | 22.46M | 26.31M | 19.71M | 22.01M | 17.11M |
| Current Portion of Leases | 5.44M | 5.07M | 4.62M | 3.97M | 1.30M | 285.00K |
| Other Current Liabilities | 477.00K | 2.33M | 4.16M | |||
| Total Current Liabilities | 33.57M | 28.51M | 31.39M | 26.16M | 48.69M | 26.22M |
| Long-Term Leases | 39.27M | 42.07M | 47.27M | 51.89M | 53.79M | 18.51M |
| Other Long-Term Liabilities | 341.00K | 399.00K | 362.00K | 566.00K | 573.00K | 158.00K |
| Total Liabilities | 73.19M | 70.98M | 79.03M | 78.61M | 103.06M | 44.89M |
| Common Stock | 31.00K | 28.00K | 28.00K | 15.00K | 15.00K | 12.00K |
| Additional Paid-In Capital | 1.48B | 1.22B | 1.19B | 922.61M | 893.85M | 694.84M |
| Retained Earnings | -1.12B | -892.21M | -767.66M | -606.01M | -480.97M | -238.17M |
| Comprehensive Income & Other | -1.25M | 628.00K | 405.00K | 77.00K | -1.04M | -162.00K |
| Total Common Equity | 361.87M | 325.17M | 423.50M | 316.69M | 411.85M | 456.53M |
| Shareholders' Equity | 361.87M | 325.17M | 423.50M | 316.69M | 411.85M | 456.53M |
| Total Liabilities & Equity | 435.05M | 396.15M | 502.53M | 395.30M | 514.91M | 501.42M |
| Total Debt | 44.71M | 47.14M | 51.89M | 55.86M | 55.10M | 18.79M |
| Net Cash (Debt) | 339.56M | 294.66M | 388.58M | 266.13M | 380.52M | 440.45M |
| Net Cash Per Share | 1.15 | 1.04 | 1.66 | 1.77 | 3.12 | 6.64 |
| Filing Date Shares Outstanding | 349.76M | 310.80M | 283.27M | 151.12M | 150.59M | 121.59M |
| Total Common Shares Outstanding | 312.56M | 284.16M | 283.22M | 151.09M | 150.45M | 121.38M |
| Working Capital | 244.87M | 257.73M | 277.40M | 294.52M | 395.81M | 393.79M |
| Book Value Per Share | 1.16 | 1.14 | 1.50 | 2.10 | 2.74 | 3.76 |
| Tangible Book Value | 361.87M | 325.17M | 423.50M | 316.69M | 411.85M | 456.53M |
| Tangible Book Value Per Share | 1.16 | 1.14 | 1.50 | 2.10 | 2.74 | 3.76 |
| Machinery | 9.63M | 9.65M | 10.02M | 11.39M | 10.48M | 5.66M |
| Construction In Progress | 11.23M | |||||
| Leasehold Improvements | 16.31M | 16.31M | 16.31M | 18.17M | 17.84M | 795.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -287.22M | -124.55M | -161.65M | -125.04M | -242.81M | -122.76M |
| Depreciation & Amortization | 2.94M | 3.11M | 3.81M | 3.73M | 2.64M | 829.00K |
| Asset Writedown & Restructuring Costs | 152.00M | 9.50M | 27.15M | 102.00M | 10.85M | |
| Loss (Gain) From Sale of Investments | -2.92M | -5.09M | -7.43M | -6.95M | -994.00K | 108.00K |
| Stock-Based Compensation | 29.85M | 24.90M | 26.97M | 26.23M | 20.11M | 8.33M |
| Other Operating Activities | 15.34M | |||||
| Change in Accounts Payable | 288.00K | 513.00K | -1.53M | -886.00K | 676.00K | 1.34M |
| Change in Other Net Operating Assets | 7.04M | -3.84M | 3.27M | 1.70M | 15.11M | 6.36M |
| Operating Cash Flow | -98.02M | -95.45M | -109.42M | -101.22M | -103.26M | -79.60M |
| Capital Expenditures | -59.00K | -128.00K | -60.00K | -1.77M | -14.55M | -11.21M |
| Sale (Purchase) of Intangibles | -154.00M | -9.50M | -22.50M | -20.00M | -2.00M | -7.68M |
| Investment in Securities | -19.86M | 110.05M | -134.06M | -69.44M | -54.53M | -45.70M |
| Investing Cash Flow | -173.92M | 100.42M | -156.62M | -91.22M | -71.08M | -64.59M |
| Issuance of Common Stock | 264.69M | 1.10M | 240.70M | 1.29M | 98.08M | 319.45M |
| Other Financing Activities | -16.34M | 553.00K | ||||
| Financing Cash Flow | 248.34M | 1.10M | 240.70M | 1.29M | 98.08M | 439.40M |
| Net Cash Flow | -23.60M | 6.07M | -25.34M | -191.14M | -76.27M | 295.21M |
| Free Cash Flow | -98.08M | -95.58M | -109.48M | -102.99M | -117.81M | -90.81M |
| Free Cash Flow Per Share | -0.33 | -0.34 | -0.47 | -0.69 | -0.97 | -1.37 |
| Levered Free Cash Flow | -210.46M | -66.76M | -84.59M | -104.91M | -67.97M | -61.18M |
| Unlevered Free Cash Flow | -210.46M | -66.76M | -84.59M | -104.91M | -67.97M | -61.18M |
| Change in Working Capital | 7.33M | -3.33M | 1.74M | 813.00K | 15.79M | 7.71M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 4.91B | 1.06B | 709.65M | 320.72M | 646.73M | 1.89B |
| Enterprise Value | 4.57B | 741.32M | 299.28M | 33.92M | 335.69M | 1.42B |
| Last Close Price | 14.35 | 3.72 | 2.51 | 2.13 | 4.31 | 15.58 |
| PB Ratio | 12.39 | 3.25 | 1.68 | 1.01 | 1.57 | 4.14 |
| P/TBV Ratio | 13.54 | 3.25 | 1.68 | 1.01 | 1.57 | 4.14 |
| Debt / Equity Ratio | 0.12 | 0.14 | 0.12 | 0.18 | 0.13 | 0.04 |
| Net Debt / Equity Ratio | -0.94 | -0.91 | -0.92 | -0.84 | -0.92 | -0.96 |
| Net Debt / EBITDA Ratio | 2.30 | 2.30 | 2.62 | 1.93 | 2.62 | 4.60 |
| Net Debt / FCF Ratio | 3.46 | 3.08 | 3.55 | 2.58 | 3.23 | 4.85 |
| Quick Ratio | 8.08 | 9.77 | 9.57 | 11.98 | 8.96 | 15.81 |
| Current Ratio | 8.29 | 10.04 | 9.84 | 12.26 | 9.13 | 16.02 |
| Return on Equity (ROE) | -78.25% | -33.27% | -43.68% | -34.33% | -55.92% | -43.41% |
| Return on Assets (ROA) | -21.39% | -18.28% | -21.22% | -19.44% | -18.16% | -19.27% |
| Return on Capital Employed (ROCE) | -37.50% | -35.70% | -32.30% | -38.30% | -31.70% | -20.30% |
| Earnings Yield | -6.91% | -11.80% | -22.78% | -38.99% | -37.54% | -6.50% |
| FCF Yield | -2.00% | -9.06% | -15.43% | -32.11% | -18.22% | -4.81% |
| Buyback Yield / Dilution | -4.44% | -21.26% | -55.69% | -23.08% | -84.08% | -215.11% |